Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preoperative endocrine therapy for breast cancer
Autore:
Cheung, KL; Howell, A; Robertson, JFR;
Indirizzi:
Univ Manchester, Christie Hosp, CRC, Dept Med Oncol, Manchester M13 9PL, Lancs, England Univ Manchester Manchester Lancs England M13 9PL M13 9PL, Lancs, England City Hosp, Professorial Unit Surg, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB t Surg, Nottingham NG5 1PB, England
Titolo Testata:
ENDOCRINE-RELATED CANCER
fascicolo: 3, volume: 7, anno: 2000,
pagine: 131 - 141
SICI:
1351-0088(200009)7:3<131:PETFBC>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-STIMULATING FACTOR; PRIMARY TAMOXIFEN THERAPY; PRIMARY SYSTEMIC THERAPY; PRIMARY MEDICAL THERAPY; PRIMARY TUMOR REMOVAL; ELDERLY PATIENTS; RANDOMIZED TRIAL; AROMATASE INHIBITORS; ESTROGEN-RECEPTOR; HORMONE-THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Robertson, JFR City Hosp, Professorial Unit Surg, Hucknall Rd, Nottingham NG5 1PB, England City Hosp Hucknall Rd Nottingham England NG5 1PB , England
Citazione:
K.L. Cheung et al., "Preoperative endocrine therapy for breast cancer", ENDOCR-R CA, 7(3), 2000, pp. 131-141

Abstract

The preoperative use of systemic therapy for primary breast cancer has thepotential to downstage tumours. This would render suitable for breast conservation some tumours that were unsuitable at initial presentation, or would convert some inoperable locally advanced breast cancers into tumours thatare operable. No survival benefit has been demonstrated for neoadjuvant chemotherapy compared with the same therapy given in an adjuvant setting. Preoperative endocrine therapy, in contrast to neoadjuvant chemotherapy, has fewer side effects and has the potential additional advantage that it can becontinued throughout the perioperative period. Current data have shown that, in patients with an oestrogen receptor (ER)-positive tumour, a response approaching 70% could be reached in approximately 3 months using traditional endocrine manipulation such as tamoxifen. Randomised clinical trials are warranted to demonstrate the superiority of preoperative endocrine therapy over conventional adjuvant endocrine therapy, to define the optimum duration of therapy, and to identify the best endocrine agents. Both clinical and laboratory studies are also required to identify factors (in addition to ER) that would precisely predict the response and hence to select appropriatepatients and to improve existing methods of monitoring response.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 05:45:51